title: Satisfaction of well-controlled type 2 diabetes patients with three-monthly and six-monthly monitoring.
abstract: BACKGROUND
  Patient's satisfaction with monitoring frequency is of interest when implementing six-monthly monitoring for well-controlled type 2 diabetes patients. Here we want to determine the satisfaction of well-controlled type 2 diabetes patients with either three-monthly or six-monthly diabetes monitoring and their future preference.
  
  
  METHODS
  Survey among 2215 well-controlled type 2 diabetes patients (not using insulin, HbA1c ≤58 mmol/mol, systolic blood pressure ≤145 mmHg and total cholesterol ≤5.2 mmol/l) who participated in the EFFIMODI study, a randomised controlled patient-preference equivalence trial. At baseline, participants were asked whether they had a strong preference for three-monthly or six-monthly monitoring or not. If not, they were randomised to either three-monthly or six-monthly monitoring, while the others were monitored according to their preference. After eighteen months, all participants were asked whether they were satisfied with the monitoring frequency and about their future preference. Patient characteristics associated with satisfaction were also examined.
  
  
  RESULTS
  Most patients (70.8%) would like to continue their monitoring frequency. Patients from the preference groups were more often satisfied than randomised patients (92.7% and 88.1%, respectively) and patients monitored three-monthly were more often satisfied than patients monitored six-monthly (93.5% and 88.5%, respectively). Higher age, better physical health, less diabetes-related distress, higher diabetes treatment satisfaction and less perceived hyper- and hypoglycaemias were associated with a higher monitoring satisfaction.
  
  
  CONCLUSIONS
  Most well-controlled type 2 diabetes patients were satisfied with their monitoring frequency and would like to continue it. Although the satisfaction for three-monthly monitoring was slightly higher, the satisfaction with six-monthly monitoring was still rather high (88.5%).
  
  
  BACKGROUND
  Current controlled trials ISRCTN93201802.
authors.affiliation: Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, Netherlands. P.Wermeling@umcutrecht.nl
authors.forename: Paulien R
authors.initials: PR
authors.lastname: Wermeling
authors.forename: Jolien
authors.initials: J
authors.lastname: Janssen
authors.forename: Kees J
authors.initials: KJ
authors.lastname: Gorter
authors.forename: Joline W J
authors.initials: JW
authors.lastname: Beulens
authors.forename: Guy E H M
authors.initials: GE
authors.lastname: Rutten
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015190:Blood Glucose Self-Monitoring / Q000523:psychology* / Q000706:statistics & numerical data; D003924:Diabetes Mellitus, Type 2 / Q000517:prevention & control* / Q000628:therapy; D005194:Family Practice / Q000379:methods; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D008019:Life Style; D008297:Male; D008875:Middle Aged; D009426:Netherlands; D017060:Patient Satisfaction / Q000706:statistics & numerical data*; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D006442:Glycated Hemoglobin
references.citation: Diabetes Care. 2002 Nov;25(11):1933-9
references.pmid: 12401735
references.citation: BMJ. 1997 Jan 18;314(7075):174-7
references.pmid: 9022429
references.citation: Diabetes Care. 1995 Jun;18(6):754-60
references.pmid: 7555499
references.citation: BMJ. 1989 Jul 29;299(6694):313-5
references.pmid: 2504416
references.citation: Health Policy. 1996 Jul;37(1):53-72
references.pmid: 10158943
references.citation: Diabetes Res Clin Pract. 2011 Dec;94(3):311-21
references.pmid: 22079683
references.citation: BMJ. 2004 Jan 24;328(7433):204
references.pmid: 14726370
references.citation: Med Care. 1992 Jun;30(6):473-83
references.pmid: 1593914
references.citation: J Gen Intern Med. 1999 Apr;14(4):223-9
references.pmid: 10203634
references.citation: CMAJ. 1998 Oct 6;159(7):777-83
references.pmid: 9805023
references.citation: Cardiovasc Diabetol. 2012 Oct 05;11:121
references.pmid: 23039172
references.citation: Int J Clin Pharm. 2011 Dec;33(6):942-8
references.pmid: 21918840
references.citation: Swiss Med Wkly. 2005 Mar 5;135(9-10):139-44
references.pmid: 15832232
references.citation: J Am Soc Nephrol. 2004 Jan;15(1):210-8
references.pmid: 14694175
references.citation: Int J Qual Health Care. 2003 Oct;15(5):399-405
references.pmid: 14527983
references.citation: BMJ. 1998 Jan 31;316(7128):360
references.pmid: 9487173
references.citation: Diabetes Res Clin Pract. 2010 Feb;87(2):252-60
references.pmid: 19932517
references.citation: J Gen Intern Med. 1999 Apr;14(4):230-5
references.pmid: 10203635
references.citation: Ann Fam Med. 2010 Sep-Oct;8(5):410-7
references.pmid: 20843882
references.citation: Diabetes Educ. 2012 May-Jun;38(3):397-408
references.pmid: 22446035
references.citation: BMC Fam Pract. 2010 May 11;11:35
references.pmid: 20459820